Mucopolysaccharidosis I cats mount a cytotoxic T lymphocyte response after neonatal gene therapy that can be blocked with CTLA4-Ig.
about
Precision editing of large animal genomesGene therapy for mucopolysaccharidosisImpact of age at administration, lysosomal storage, and transgene regulatory elements on AAV2/8-mediated rat liver transductionImproved retroviral vector design results in sustained expression after adult gene therapy in mucopolysaccharidosis I mice.A self-inactivating gamma-retroviral vector reduces manifestations of mucopolysaccharidosis I in miceNeonatal gene therapy with a gamma retroviral vector in mucopolysaccharidosis VI cats.Strategies to modulate immune responses: a new frontier for gene therapyHepatic gene transfer as a means of tolerance induction to transgene productsLiver-directed gene therapy corrects cardiovascular lesions in feline mucopolysaccharidosis type IMinicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of α-L-iduronidase in mice with mucopolysaccharidosis type IDevelopment of Gene Transfer for Induction of Antigen-specific Tolerance.Perinatal gene transfer to the liver.Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I.A review of gene therapy in canine and feline models of lysosomal storage disorders.Specific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis I.Gene therapy for lysosomal storage diseases (LSDs) in large animal models.Gene therapy approaches for lysosomal storage disease: next-generation treatment.Effect of neonatal gene therapy on lumbar spine disease in mucopolysaccharidosis VII dogsNeonatal cellular and gene therapies for mucopolysaccharidoses: the earlier the better?Clinical characterization of cardiovascular abnormalities associated with feline mucopolysaccharidosis I and VILarge animal models of neurological disorders for gene therapy.Recent advances in gene therapy for lysosomal storage disorders.Long-term, high-level hepatic secretion of acid α-glucosidase for Pompe disease achieved in non-human primates using helper-dependent adenovirus.AAV-mediated gene therapy for metabolic diseases: dosage and reapplication studies in the molybdenum cofactor deficiency model.Altering α-dystroglycan receptor affinity of LCMV pseudotyped lentivirus yields unique cell and tissue tropismNeonatal gene transfer using lentiviral vector for murine Pompe disease: long-term expression and glycogen reduction.
P2860
Q24611750-BC62A40D-4988-4152-B835-57970255B289Q24631135-D50D5A1B-20C4-4CE9-8999-E62D70DAAE83Q27307010-EAAFB18A-E841-46BF-8DF2-0B49B6EEFFA8Q30493396-A28EC814-8923-4F43-9F6E-0A5279665C1FQ30493690-A4A058CA-3A89-4E96-B643-310521B64FC3Q30513972-DD50A1F3-F0A6-46A2-A4BE-207E34026E45Q33713999-2775F006-204C-462F-8673-192D48C748E5Q33775537-C9B03325-C654-46C2-BFCD-7E1ABB5B94B9Q34384047-4D7E9A62-8ABD-4CD3-80C3-9C81A835E132Q34621690-EDFB9D4D-6140-49EE-9343-16080C9378E0Q34794525-0C9AC5F8-C606-477C-8979-DAD6EDA35518Q35238390-96E9B595-7449-43F6-AA2E-AE4A087D1669Q35559945-6430D3EA-C971-4458-9A5F-53259D7C3639Q35894676-C0DB2ADE-1B7E-4EB4-8BCD-6DA7B1C48138Q35911463-FD96652F-2F67-407B-B367-F504118B603CQ35923476-10733F69-7563-411B-A03C-CD00DFCC6E18Q36147475-D402E5B4-C2FF-49BC-98F5-38463E79A212Q36195519-6AD08555-BCAB-4D05-AED0-9E9799576BF8Q36582259-A2DEFCF0-5BE3-4FFB-8BF8-9B72C08C4C5EQ37193936-C20D6BC0-EE00-4734-9F33-9D9EDBBFE480Q37265519-D7930E21-E01B-4862-B778-21FCD02FE586Q38546492-BCEC2BDE-0DFC-40D3-91A3-2BEDDF00E1B7Q38846270-2429DC9C-99CD-4237-9E97-D6BF5B47807EQ41849765-7E7DC2D1-C694-4C93-B33A-74874EDDD64FQ41980779-AACD657E-9140-4FE7-965F-005099A16FCCQ45855941-8BAD0568-5504-4553-8004-161459E9A6C5
P2860
Mucopolysaccharidosis I cats mount a cytotoxic T lymphocyte response after neonatal gene therapy that can be blocked with CTLA4-Ig.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Mucopolysaccharidosis I cats m ...... can be blocked with CTLA4-Ig.
@en
Mucopolysaccharidosis I cats m ...... can be blocked with CTLA4-Ig.
@nl
type
label
Mucopolysaccharidosis I cats m ...... can be blocked with CTLA4-Ig.
@en
Mucopolysaccharidosis I cats m ...... can be blocked with CTLA4-Ig.
@nl
prefLabel
Mucopolysaccharidosis I cats m ...... can be blocked with CTLA4-Ig.
@en
Mucopolysaccharidosis I cats m ...... can be blocked with CTLA4-Ig.
@nl
P2093
P1433
P1476
Mucopolysaccharidosis I cats m ...... t can be blocked with CTLA4-Ig
@en
P2093
Anne Traas
Baomei Wang
Karyn Cullen
Katherine P Ponder
Mark E Haskins
N Matthew Ellinwood
Patty O'Donnell
Tina M Primeau
P356
10.1016/J.YMTHE.2006.03.015
P50
P577
2006-05-12T00:00:00Z